J.J. Kim

Inhibition of tumor necrosis factor-α-induced apoptosis by Asparagus cochinchinensis in Hep G2 cells

Abstract A human hepatoma cell line, Hep G2 cells, is a reliable system for the study of alcohol-induced hepatotoxicity. In this study, we investigated the effect of an aqueous extract of Asparagus cochinchinensis MERRIL (Liliaceae) roots (ACAE) on ethanol (EtOH)-induced cytotoxicity in Hep G2 cells. ACAE (1–100 μg/ml) dose-dependently inhibited the EtOH-induced tumor necrosis factor-α (TNF-α) secretion. ACAE (1–100 μg/ml) also inhibited the EtOH and TNF-α-induced cytotoxicity. Furthermore, we found that ACAE inhibited the TNF-α-induced apoptosis of Hep G2 cells. These results suggest that ACAE may prevent the EtOH-induced cytotoxicity through inhibition of the apoptosis of Hep G2 cells.

Commissioning of the PLS-II

After 14 years of successful operation, the Pohang Light Source (PLS) has completed PLS-II upgrade to meet the increasing demand from the growing user community. The PLS-II upgrade has increased the beam energy from 2.5 GeV to 3 GeV; the number of insertion devices has been increased by a factor of two (20 IDs); and the beam current has been increased to 400 mA from 200 mA. The beam emittance has been reduced to below 10 nm while retaining the existing PLS tunnel as well as the existing injection system. During the six months of commissioning in the latter half of 2011, we have successfully achieved 14 insertion device operations and top-up operations with 100 mA beam current and 5.8 nm beam emittance. In this paper, we report the experimental results obtained from the PLS-II commissioning.

The stem of Sinomenium acutum inhibits mast cell-mediated anaphylactic reactions and tumor necrosis factor-α production from rat peritoneal mast cells.

The aqueous extract of Sinomenium acutum stem (SSAE) (0.1-1000 mg/kg) dose-dependently inhibited systemic anaphylactic reaction induced by compound 48/80 in mice. In particular, SSAE reduced compound 48/80-induced anaphylactic reaction with 50% at the dose of 1000 mg/kg. SSAE (100-1000 mg/kg) also significantly inhibited local anaphylactic reaction activated by anti-dinitrophenyl (DNP) IgE. When mice were pretreated with SSAE at a concentration ranging from 0.1 to 1000 mg/kg, the plasma histamine levels were reduced in a dose-dependent manner. SSAE (1-1000 microg/ml) dose-dependently inhibited histamine release from the rat peritoneal mast cells (RPMCs) activated by compound 48/80 or anti-DNP IgE. In addition, SSAE (0.1 microg/ml) had a significant inhibitory effect on anti-DNP IgE-induced tumor necrosis factor-alpha (TNF-alpha) production. These results indicate that SSAE inhibits mast cell-mediated anaphylactic reactions and TNF-alpha production from mast cells.

Effect of Korean folk medicine 'Chung-Dae-San' on mast cell-dependent anaphylactic reaction

We investigated the effect of the herbal formulation Chung-Dae-San (CDS) on anaphylactic reactions. CDS inhibited compound 48/80-induced anaphylactic shock 100% with the dose of 10(0) g/kg body weight (BW). When CDS was given as pretreatment at concentrations ranging from 10(-4) to 10(0) g/kg BW, the serum histamine levels induced by compound 48/80 were reduced in a dose-dependent manner. We also investigated the effect of CDS on mast cell-dependent passive cutaneous anaphylaxis (PCA) activated by anti-dinitrophenyl (DNP) IgE antibody. CDS potently inhibited PCA when administered orally, topically, intraperitoneally or intradermally. However, it did not show inhibitory activity when administered intravenously. CDS dose-dependently inhibited the histamine release from the rat peritoneal mast cells (RPMC) by compound 48/80 and anti-DNP IgE. Moreover, the level of cAMP in RPMC, when CDS was added, significantly increased about 4-fold at 4 min compared with that of basal cells. These results indicate that CDS may possess strong antianaphylactic activity and also suggest the differential activity following administration routes may be caused by difference in bioavailability.

FRI0131 Analysis of Magnetic Resonance Imaging Scoring System for Facet Joint in Ankylosing Spondylitis

Objectives The aim of this study is to identify radiographic damages at affected facet joint of the spine and also to compare radiographic inflammatory activity between facet joints and spinal disco-vertebral units (DVUs) in ankylosing spondylitis (AS). Methods The whole spine magnetic resonance imaging (MRI) from total 46 AS patients (male =38, 82.6%) were reviewed. Three different methods including the Ankylosing Spondylitis spine MRI-activity (ASspiMRI-a), the Berlin modification of the ASspiMRI-a, and the Spondyloarthritis Research Consortium of Canada (SPARCC) scoring system for spinal inflammation were evaluated. Facet joint scoring system identified bone marrow edema, erosion, and ankylosis at the same level of each 23 DVU, which were scored between 0 to 3 points for both sides at each lesion. Total facet joint score means sum of scores of edema, erosion, and ankylosis at each level. Results Total 131 facet joint lesions, consisting of 98 for bone edema, 18 of bone erosion, and 15 of bony ankylosis, were identified. Most frequent facet joint lesions were detected at levels of C7-T1 (8.4%), T1-T2 (9.9%), L2-L3 (9.2%), and L3-L4 (9.9%) among total 131 facet joint lesions, whereas spinal inflammatory lesions were frequently identified at mid-thoracic spine level especially at T3 to T8. Total facet joint scores were closely correlated with ASspiMRI-a, Berlin, and SPARCC scores (r =0.372, p=0.011; r =0.414, p=0.004; r =0.400, p=0.006, respectively). However, the number of affected spinal joint at each DVU was not associated with that of facet joint lesions, indicating little possibility for concurrence of spinal DUVs and facet joint lesions. Conclusions This study implicates that inflammatory disease activity at facet joint was associated with that at DUVs of spine in AS. Discordance between DUVs and facet joint for concurrence of inflammation was observed. Close attention for facet joint involvement in AS should be needed. Disclosure of Interest None declared DOI 10.1136/annrheumdis-2014-eular.3418

THU0404 Clinicopathological Analysis of 18 Cases of Specific Subcutaneous Sarcoidosis in South Korea

Background Sarcoidosis is a multisystemic granulomatous disorder of uncertain etiology, which is rare in Asia. In particular, subcutaneous sarcoidosis is a specific cutaneous lesion of sarcoidosis that is rarely reported. Objectives The aim of this study is to evaluate the clinicopathological features of 18 pateints with specific subcutaneous sarcoidosis and their relationship with systemic feature of the disease. Methods All patients performed skin biopsy and diagnosed with subcutaneous sarcoidosis from 2003 to 2013 were reviewed. Histological finding and clinical characteristics were analyzed. Results Eighteen patients with specific subcutaneous sarcoidosis were observed. Mean age at diagnosis was 51.4 years and female were dominant (17 patients, 94%). The initial lesions of the patients were 12 infiltrated nodulopapule, 3 maculopapular eruption, and 2 scar sarcoidosis. Subcutaneous lesions were most frequently located in the extremities. Four (22.2%) of 18 patients demonstrated only specific cutaneous involvement during follow-up period and the rest of the patients presented systemic involvement which included 14 hilar and mediastinal lymphadenopathy with or wihout lung parenchymal lesion, 3 arthritis, 2 uveitis, or 1 splenic involvement. Serum angiotensin-converting enzyme level in patients with systemic involvement tends to be higher than those without, although there was no statistical significance. In most of the patients, subcutaneous nodules appeared at the beginning of the disease and only 3 cases present skin nodules within 6 months after diagnosis. Twelve (66.5%) patients were treated with oral steroid and 4 (22.2%) patients treated with hydroxychloroquine or colchicine. The nodules remitted spontaneously in less than 1 year in 2 patients. Three patients present relapse course with lung involvement and were treated with oral steroid with azathioprine, which showed partial remission. Conclusions Specific subcutaneous sarcoidosis is a quite uniform clinicopathological entity usually appearing at the beginning of the disease. It may present with nonsevere systemic involvement and showed favorable clinical outcome. Disclosure of Interest : None declared DOI 10.1136/annrheumdis-2014-eular.5278

AB0410 Effect of Anti-Tumor Necrosis Factor Alpha Treatment of Rheumatoid Arthritis and Chronic Kidney Disease

Background Rheumatoid arthritis (RA) and chronic kidney disease (CKD) are very prevalent and so often coincide. Among various anti-inflammatory agents, TNF-α blocking drugs reportedly stabilize renal function in RA patients with CKD and/or secondary renal amyloidosis by suppressing inflammation. However, there are no available data supporting the efficacy of anti-TNF-α agents in a larger population of RA patients with renal insufficiency. Objectives To investigate the impact of anti-tumor necrosis factor alpha (TNF-α) therapy on progression of CKD in patients with RA. Methods Seventy patients with RA and CKD were retrospectively analyzed. Outcomes were evaluated using the difference in the annual change of estimated glomerular filtration rate (eGFR) between patients with treated with anti-TNF-α or without. Results There was a tendency toward stabilization of eGFR after a median of 2.6 years (interquartile range, 1.2–4.2 years) from 50.3±8.4 ml/min/1.73 m2 to 54.5±16.0 ml/min/1.73 m2 in patients received anti-TNF-α therapy (p=0.084). Conversely, eGFR decreased significantly in patients not receiving anti-TNF-α therapy after a median of 3.0 years (interquartile range, 1.8–4.6 years) from 50.9±7.7 ml/min/1.73 m2 to 43.7±10.9 ml/min/1.73 m2 (p<0.001). The annual change of eGFR was significantly different between patients treated with anti-TNF-α drugs and without (2.0±7.0 ml/min/1.73 m2/y versus -2.9±5.8 ml/min/1.73 m2/y; difference in mean values, -4.9 ml/min/1.73 m2/y; 95% confidence interval, -7.5 to -2.2; p=0.002). Use of anti-TNF-α drugs was also significantly associated with positive annual change of eGFR in logistic regression analysis (p=0.009). Conclusions Among patients with RA and CKD, treatment with anti-TNF-α drugs was associated with less renal function decline. Anti-TNF-α drugs may be beneficial for managing RA combined with CKD. Disclosure of Interest None declared DOI 10.1136/annrheumdis-2014-eular.4801